Ichiro Nakano

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Neuro Oncol 13:622-34. 2011
  2. ncbi Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb
    Takeshi Miyazaki
    Department of Neurological Surgery, Dardinger, Center for Neuro Oncology, James Cancer Hospital and The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 18:1268-80. 2012
  3. ncbi CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway
    Mayumi Jijiwa
    Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 6:e24217. 2011
  4. ncbi BMPing off glioma stem cells
    Ichiro Nakano
    Department of Neurological Surgery, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Cancer Cell 13:3-4. 2008
  5. ncbi [Cancer stem cells in malignant glioma-the mechanism of cancer initiation and the therapeutic development]
    Ichiro Nakano
    Department of Neurological Surgery, The Ohio State University, Ohio, USA Ichiro Nakano osumc edu
    No Shinkei Geka 38:879-89. 2010

Collaborators

  • Harley I Kornblum
  • Takeshi Miyazaki
  • Kazuo Shin-ya
  • Mayumi Jijiwa
  • William H Yong
  • Jason A de Jesus
  • Kaushal Joshi
  • Paul S Mischel
  • Nicholas Orozco
  • Tiffany Huang
  • Ichiyo Shibahara
  • Habibe Demir
  • Soledad Fernandez
  • Snehalata Gupta
  • Vedat O Yildiz
  • Crystal Leung

Detail Information

Publications5

  1. ncbi Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Neuro Oncol 13:622-34. 2011
    ..Together, this study may be the first model to partially target stemlike GBM cells through a MELK-mediated pathway with siomycin A to pave the way for effective treatment of GBM...
  2. ncbi Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb
    Takeshi Miyazaki
    Department of Neurological Surgery, Dardinger, Center for Neuro Oncology, James Cancer Hospital and The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 18:1268-80. 2012
    ..Glioma stem cells (GSC) are a critical therapeutic target of glioblastoma multiforme (GBM)...
  3. ncbi CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway
    Mayumi Jijiwa
    Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 6:e24217. 2011
    ..Collectively, these data indicate that a subset of GBM expresses high CD44 in BTSC, and its growth may depend on CD44v6/AKT pathway...
  4. ncbi BMPing off glioma stem cells
    Ichiro Nakano
    Department of Neurological Surgery, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Cancer Cell 13:3-4. 2008
    ..These findings document the importance of the BMP signaling system in BTSC as well as that of taking heterogeneity into account when studying BTSC as potential targets for therapy...
  5. ncbi [Cancer stem cells in malignant glioma-the mechanism of cancer initiation and the therapeutic development]
    Ichiro Nakano
    Department of Neurological Surgery, The Ohio State University, Ohio, USA Ichiro Nakano osumc edu
    No Shinkei Geka 38:879-89. 2010
    ..In this study, we summarize the recent findings and approaches in the cancer stem cell field, mainly focusing on malignant glioma stem cells, and also describe potential future directions in this area...